Physician profile
Cesar Preciado
NPI 1366033573
$6,477.21
in general payments reported to CMS, 2019-2025
12 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $1,009 · 2023: $2,137 · 2024: $1,797 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,274.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,492.14 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $1,288.13 | 2022-2025 | |
| Alkermes, INC. | $784.77 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $753.85 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.59 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $253.30 | 2023-2024 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $164.23 | 2022-2023 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $120.70 | 2022-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $113.78 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $80.04 | 2023 | Auvelity |
| Lundbeck LLC | $61.52 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Preciado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.